Correlated Drug Terms (1)

---

	Name (Synonyms)	Correlation
drug1608	Nitric Oxide-Releasing Drug Wiki	1.00

Correlated MeSH Terms (4)

---

	Name (Synonyms)	Correlation
D003141	Communicable Diseases NIH	0.09
D007239	Infection NIH	0.06
D045169	Severe Acute Respiratory Syndrome NIH	0.05
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Measuring the proportion of patients with clinical worsening (defined by a requirement of FIO2 >50% and/or mechanical respiratory assistance)

Measure: Evaluate the efficacy of ruxolitinib in the treatment of COVID-19 severe acute respiratory syndrome

Time: during 14 days after the commencement of treatment

---

Secondary Outcomes

Measure: Evaluate the median duration of hospitalization.

Time: after 45 days of commencement of treatment.

---

Description: Evaluation at the beginning (baseline), middle and end of the treatment with ruxolitinib of PCR, LDH, ESD, Ferritin and IL-6 (if available).

Measure: Evaluate the evolution of systemic inflammation parameters.

Time: after 45 days of commencement of treatment.

---

Measure: Evaluate COVID-19 mortality rate

Time: after 45 days of treatment.

---

Measure: Evaluate the proportion of the requirement of mechanical ventilation.

Time: with a total follow-up of 45 days

---

Measure: Evaluate ruxolitinib adverse reactions

Time: with a total follow-up of 45 days.

---

Measure: Evaluate the proportion of secondary infections during the treatment with ruxolitinib

Time: after 45 days of commencement of treatment.

---